Dietary Glycomacropeptide Supports Growth and Reduces the Concentrations of Phenylalanine in Plasma and Brain in a Murine Model of Phenylketonuria ,
Authors:
Open Access
- 1 February 2008
- journal article
- research article
- Published by Elsevier in The Journal of Nutrition
- Vol. 138 (2) , 316-322
Abstract
Phenylketonuria (PKU) is a genetic disorder caused by deficiency of phenylalanine hydroxylase (PAH) that requires life-long adherence to a low-phenylalanine (Phe) diet. Glycomacropeptide (GMP) is uniquely suited to the nutritional management of PKU, because pure GMP contains no Phe. Our aim was to assess how ingestion of diets containing GMP support growth and affect the concentrations of amino acids in plasma and brains of mice with a deficiency of PAH, the Pahenu2 mouse (PKU mouse). Experiments were conducted in 4- to 6-wk-old wild-type (WT) (C57Bl/6) and PKU mice fed diets containing 20% protein from casein, amino acids, or GMP supplemented with limiting indispensable amino acids (IAA). PKU mice fed the GMP diet showed gains in body weight, feed efficiency, and a protein efficiency ratio that did not differ from the amino acid diet. The concentrations of isoleucine and threonine in plasma showed a significant 2- to 3-fold increase for WT and PKU mice fed GMP compared with casein or amino acid diets, respectively. PKU mice fed the GMP diet had decreased concentrations of Phe in plasma (11% decrease) and in 5 regions of the brain (20% decrease) compared with the amino acid diet. The concentration of Phe in the brain was inversely correlated with the concentrations of isoleucine, threonine, and valine in plasma (R2 = 0.74; P < 0.0001), suggesting competitive inhibition of Phe transport into the brain. In summary, PKU mice fed GMP showed comparable growth and reduced concentrations of Phe in plasma and the brain compared with an amino acid diet. These data support the use of GMP supplemented with IAA as an alternative source of dietary protein for individuals with PKU.Keywords
This publication has 28 references indexed in Scilit:
- Acceptable low-phenylalanine foods and beverages can be made with glycomacropeptide from cheese whey for individuals with PKUMolecular Genetics and Metabolism, 2007
- The effects of large neutral amino acid supplements in PKU: An MRS and neuropsychological studyMolecular Genetics and Metabolism, 2007
- Double blind placebo control trial of large neutral amino acids in treatment of PKU: Effect on blood phenylalanineJournal of Inherited Metabolic Disease, 2007
- Effects of Bovine α‐Lactalbumin and Casein Glycomacropeptide–enriched Infant Formulae on Faecal Microbiota in Healthy Term InfantsJournal of Pediatric Gastroenterology and Nutrition, 2006
- Complete correction of hyperphenylalaninemia following liver-directed, recombinant AAV2/8 vector-mediated gene therapy in murine phenylketonuriaGene Therapy, 2005
- National Institutes of Health Consensus Development Conference Statement: Phenylketonuria: Screening and Management, October 16–18, 2000Pediatrics, 2001
- Large neutral amino acids block phenylalanine transport into brain tissue in patients with phenylketonuriaJournal of Clinical Investigation, 1999
- Effect of Increasing Dietary Threonine Intakes on Amino Acid Metabolism of the Central Nervous System and Peripheral Tissues in Growing RatsPediatric Research, 1998
- Effects of diet-induced hyperthreoninemia. I) amino acid levels in the central nervous system and peripheral tissuesLife Sciences, 1993
- Some Characteristics of Threonine Transport Across the Blood‐Brain Barrier of the RatJournal of Neurochemistry, 1988